Edgar Filing: ACHILLION PHARMACEUTICALS INC - Form 4

ACHILLION PHARMACEUTICALS INC

Form 4

Common

\$0.001 par 12/20/2013

Common 12/20/2013

Stock,

value

Stock,

value

\$0.001 par

December 24, 2013

FORM		B APPROVAL							
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							r: 3235-0287 January 31,		
Check this b		STATEMENT OF CHANCES IN DENEFICIAL OWNEDSHID OF							
subject to Section 16. Form 4 or		STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES					ed average hours per se 0.5		
obligations may continu <i>See</i> Instructi 1(b).	may continue. See Instruction See Instruction See Instruction 30(h) of the Investment Company Act of 1940								
(Print or Type Res	ponses)								
1. Name and Address of Reporting Person * QVT Associates GP LLC			suer Name and Ticker or o	5. Relationship of Reporting Person(s) to Issuer					
			IILLION RMACEUTICALS II	NC	(Check all applicable)				
			HN]		DirectorX 10% Owner				
(Last) (First) (Middle) 1177 AVENUE OF THE			th/Day/Year) 0/2013		Officer (give title Other (specify below)				
AMERICAS,		1 21 2	0/2013						
			Amendment, Date Original Month/Day/Year)		6. Individual or Joint/Group Filing(CheckApplicable Line)_X_ Form filed by One Reporting Person				
NEW YORK,	NY 10036				Form filed by More than One Reporting Person				
(City)	(State) (Zi	(State) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned							
	an	xecution Date, i	Code (Instr. 3, 4 and 5)		Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
_							Through QVT		

S

S

32,155 D

75,000 D

\$

3.16

Fund IV LP,

QVT Fund V

Quintessence Fund L.P.

Through QVT

Fund IV LP,

QVT Fund V

LP and

LP and

11,365,383 I

11,290,383 I

Edgar Filing: ACHILLION PHARMACEUTICALS INC - Form 4

								Quintessence Fund L.P.
Common Stock, \$0.001 par value	12/23/2013	S	75,000	D	\$ 3.25	11,215,383	I	Through QVT Fund IV LP, QVT Fund V LP and Quintessence Fund L.P.
Common Stock, \$0.001 par value	12/23/2013	S	75,000	D	\$ 3.3	11,140,383	I	Through QVT Fund IV LP, QVT Fund V LP and Quintessence Fund L.P.
Common Stock, \$0.001 par value	12/23/2013	S	31,986	D	\$ 3.37	11,108,397	I	Through QVT Fund IV LP, QVT Fund V LP and Quintessence Fund L.P.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exerc	cisable and	7. Titl	le and	8. Price of	
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transact	iorNumber	Expiration D	ate	Amou	int of	Derivative	
Security	or Exercise		any	Code	of	(Month/Day/	Year)	Under	rlying	Security	
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivative	e		Secur	ities	(Instr. 5)	i
	Derivative				Securities	3		(Instr.	3 and 4)		
	Security				Acquired						1
	·				(A) or						1
					Disposed						,
					of (D)						,
					(Instr. 3,						
					4, and 5)						
					, ,						
									Amount		
						Date	Expiration		or		
						Exercisable	Date	Title N	Number		
						LACICISABIC	Dute		of		
				Code V	(A) (D)				Shares		

Reporting Owners

Relationships

Reporting Owner Name / Address

Reporting Owners 2

Edgar Filing: ACHILLION PHARMACEUTICALS INC - Form 4

Director 10% Owner Officer Other

QVT Associates GP LLC 1177 AVENUE OF THE AMERICAS 9TH FLOOR NEW YORK, NY 10036



Signatures

/s/ Arthur Chu, Managing Member

12/24/2013

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Remarks:

On December 20, 2013, QVT Fund IV LP sold 13,761 shares of Common Stock, Quintessence Fund L.P. sold 11,872 shares of and QVT Fund V LP sold 81,522 shares of Common Stock. On December 23, 2013, QVT Fund IV LP sold 23,373 shares of Quintessence Fund L.P. sold 20,162 shares of Common Stock and QVT Fund V LP sold 138,451 shares of Common Stock. A Fund IV LP directly beneficially owns 1,426,760 shares of Common Stock, Quintessence Fund L.P. directly beneficially owns of Common Stock and QVT Fund V LP directly beneficially owns 8,450,899 shares of Common Stock. QVT Associates GP L partner of QVT Fund IV LP, QVT Fund V LP and Quintessence Fund L.P. (together with QVT Fund IV LP, and QVT Fund V "Funds"). QVT Financial LP is the investment manager for the Funds and therefore may be deemed the beneficial owner of the held by the Funds. QVT Financial GP LLC is the general partner of QVT Financial LP and therefore may be deemed the beneficial ownership of the reported to the extent of its pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3